zifeng-ai/TrialReviewBench huggingface dataset:
Study: Agrawal (2019), India (PMID 30988558)
No. of patients (HSCT/CT): 16/30
Median age (range): 35 (14-76)
Chemotherapy regimen in consolidation therapy: Hyper-CVAD
Median follow-up (range, month): 17.5 (2-58)
TKI: IM/DA
Study type: R
NOS score: 7
Study: Chang (2019), China (PMID 31016870)
No. of patients (HSCT/CT): 30/40
Median age (range): 45 (21-69)
Chemotherapy regimen in consolidation therapy: BFM-like
Median follow-up (range, month): 15 (1-131)
TKI: DA
Study type: R
NOS score: 7
Study: Daver (2015), USA (PMID 25682595)
No. of patients (HSCT/CT): 16/23
Median age (range): 51 (17-84)
Chemotherapy regimen in consolidation therapy: Hyper-CVAD
Median follow-up (range, month): 130 (73-149)
TKI: IM
Study type: P
NOS score: 7
Study: Fujisawa (2017), Japan (PMID 28103625)
No. of patients (HSCT/CT): 43/22
Median age (range): 49 (18-64)
Chemotherapy regimen in consolidation therapy: Hyper-CVAD
Median follow-up (range, month): 34 (13.4-52.8)
TKI: IM
Study type: P
NOS score: 8
Study: Hatta (2018), Japan (PMID 29694642)
No. of patients (HSCT/CT): 59/37
Median age (range): 45 (15-64)
Chemotherapy regimen in consolidation therapy: HD-Ara+MTX
Median follow-up (range, month): 58.8 (4.8-96)
TKI: IM
Study type: P
NOS score: 8
Study: Jabbour (2018), USA (PMID 30501869)
No. of patients (HSCT/CT): 15/61
Median age (range): 47 (39-61)
Chemotherapy regimen in consolidation therapy: Hyper-CVAD
Median follow-up (range, month): 36 (22-63,IQR)
TKI: PO
Study type: P
NOS score: 9
Study: Kim (2015), Korea (PMID 26065651)
No. of patients (HSCT/CT): 57/25
Median age (range): 47 (17-71)
Chemotherapy regimen in consolidation therapy: DVP+HD-Ara+VP16
Median follow-up (range, month): NA
TKI: NL
Study type: P
NOS score: 9
Study: Liu (2019), China (PMID 30635765)
No. of patients (HSCT/CT): 13/14
Median age (range): 40 (21-59)
Chemotherapy regimen in consolidation therapy: COATD/HD-MTX+MA
Median follow-up (range, month): 56.5 (49-72)
TKI: NL
Study type: R
NOS score: 7
Study: Ravandi (2015), USA (PMID 26308885)
No. of patients (HSCT/CT): 12/57
Median age (range): 55 (21-80)
Chemotherapy regimen in consolidation therapy: Hyper-CVAD
Median follow-up (range, month): 67 (0.3-97)
TKI: DA
Study type: P
NOS score: 8
Study: Ravandi (2016), USA (PMID 29046900)
No. of patients (HSCT/CT): 38/40
Median age (range): 44 (22-60)
Chemotherapy regimen in consolidation therapy: Hyper-CVAD
Median follow-up (range, month): 36 (9-63)
TKI: DA
Study type: P
NOS score: 8
Study: Tanguy (2013), France (PMID 22960387)
No. of patients (HSCT/CT): 24/9
Median age (range): 45 (16-59)
Chemotherapy regimen in consolidation therapy: VP+HD-Ara+MTZ
Median follow-up (range, month): 29.5 (0.6-59.8)
TKI: IM
Study type: P
NOS score: 7
Study: Thyagu (2012), Canada (PMID 22650180)
No. of patients (HSCT/CT): 16/12
Median age (range): 46(18-60)
Chemotherapy regimen in consolidation therapy: DOLD+6-MP+MTX
Median follow-up (range, month): 85 (46-110)
TKI: IM
Study type: R
NOS score: 7
Study: Togasaki (2014), Japan (PMID 24730539)
No. of patients (HSCT/CT): 13/9
Median age (range): 53 (22-72)
Chemotherapy regimen in consolidation therapy: Hyper-CVAD
Median follow-up (range, month): 25 (7-126)
TKI: IM
Study type: R
NOS score: 7
Study: Wang (2017), China (PMID 29247779)
No. of patients (HSCT/CT): 77/56
Median age (range): 37 (14-65)
Chemotherapy regimen in consolidation therapy: Hyper-CVAD
Median follow-up (range, month): 33 (4-114)
TKI: IM
Study type: R
NOS score: 7
Study: Wang (2019), China (PMID 30918339)
No. of patients (HSCT/CT): 60/74
Median age (range): NA (14-60)
Chemotherapy regimen in consolidation therapy: Hyper-CVAD
Median follow-up (range, month): 37 (7-115)
TKI: IM/DA
Study type: R
NOS score: 7